AKT1 and breast cancer: Of note, the PI3K inhibitor alpelisib, that has been recently approved in combination with fulvestrant for locally advanced or metastatic BC, by inhibiting the phosphorylation of PI3K downstream targets AKT and FoxO3a (Figure 3e) and, consequently, preserving FoxO3a nuclear sequestration, thus activation, even under GFs (IGF-1) stimulation Figure 3f), was able to slightly increase integrin α5 protein expression as soon as after 18 h incubation Figure 3g).